Skip to main content

Nihon Kohden Donates to Epilepsy Research for 11th Consecutive Year

Nihon Kohden, a U.S. market leader in precision medical products and services, donated the proceeds from the sale of one of its EEG-1200A machines to the American Epilepsy Society’s (AES) clinical and basic research fellowships for the 11th year in a row. The proceeds of the EEG system, which was purchased by Cabell Huntington Hospital, will be presented to AES at 2 p.m. on Dec. 7 during the society’s annual meeting in Baltimore.

Nihon Kohden, a leader in epilepsy and neurology instrumentation, established the donation program more than a decade ago to foster future advancements in epilepsy diagnosis and treatment. Since its inception, the company has contributed more than $275,000 to AES research programs.

“Nihon Kohden's ongoing contributions to epilepsy research have supported promising research of several new investigators,” said Page B. Pennell, MD, president of the American Epilepsy Society. “A key priority of AES is the investment in early career researchers because it helps advance our understanding of epilepsy and improve care for patients. We appreciate Nihon Kohden's commitment to research and are pleased to celebrate 11 years of continued partnership.”

Nihon Kohden’s donations have helped fund research into many critical areas, including a therapy for severe epilepsy syndromes caused by KCNT1 gene mutations, the connection between epilepsy and traumatic brain injuries, and the development of a neurophysiologic toolbox to aid in the diagnosis of epilepsy in patients with Alzheimer’s disease.

“We are dependent on research to uncover critical clinical advancements, and we need to do everything possible to encourage the next generation of researchers to continue seeking answers to help us address epilepsy,” said Dr. Samden Lhatoo, McGovern Chair in epilepsy, University of Texas, Houston, and director of epilepsy and neurophysiology, Cabell Huntington Hospital. “We deeply appreciate Nihon Kohden's ongoing support to advancing our understanding of epilepsy, as well as new methods to diagnose and treat this neurological disorder.”

Nihon Kohden’s support of AES is part of the organization’s fundraising efforts to support the society’s educational, research and training offerings. Proceeds will be designated to support post-doctoral fellowships and early career grants awarded through the Lennox & Lombroso Trust and a clinical research training fellowship awarded through the Susan S. Spencer Fund.

“We are proud of our decade of support to the American Epilepsy Society's education programs for new researchers,” said Mike Stone, Nihon Kohden America vice president of neurology sales. “It's been gratifying to see the advancements and accomplishments of each researcher as they continue to evolve the field of epilepsy. We are grateful Cabell Huntington Hospital could be part of this year's donation.”

About Nihon Kohden Corporation

Founded in Japan in 1951, Nihon Kohden is a leading manufacturer, developer and distributor of medical electronic equipment, with subsidiaries in the U.S., Europe and Asia. The company’s products are now used in more than 120 countries, and it is the largest supplier of electroencephalography products worldwide. A pioneer in transformational healthcare technology, Nihon Kohden has envisioned, designed and produced revolutionary devices, such as pulse oximeters, arrhythmia analysis, low-invasive blood volume monitoring and wireless patient monitoring. In the U.S., the company is a trusted source for patient monitoring, sleep assessment, neurology and cardiology instrumentation solutions, and has been rated No. 1 in patient monitoring or telemetry for more than 10 consecutive years (MD Buyline). For more information, visit us.nihonkohden.com.

MD Buyline is a registered service mark of MD Buyline.

Contacts:

Julie Johnson
Senior Director, Communications and Public Relations
949-238-4869
Julie_johnson@nihonkohden.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.